2021 update on the role of MRI in active surveillance for prostate cancer.

Outline of presentation:
-To compare and contrast observation strategies for lower risk and higher risk patients with prostate cancer
-To discuss MRI as a diagnostic biomarker (BM) that confirms clinical patient selections
-Highlight prognostic MRI features indicating a higher risk of progression and thus needing Rx intensification, rather than pursuing AS
-Assess the prognostic ability of the changing MRI phenotype during AS period
-Review the literature for evidence supporting the use of MRI at baseline (diagnostic/prognostic BM) and for follow-up (prognostic BM), highlighting uncertainties and limitations